Cargando…

MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma

BACKGROUND: MicroRNAs are mentioned as a small non-coding RNAs groups and aberrant miRNA expression was found in hepatocellular carcinoma (HCC) patients. AIM: To evaluate role of plasma MicroRNA-215 as a diagnostic tool in HCC patients. METHODS: A prospective study included 195 subjects: healthy con...

Descripción completa

Detalles Bibliográficos
Autores principales: El Mahdy, Hussein Ahmed, Abdelhamid, Ismail Abdelshafy, Amen, Ahmed Ibrahim, Abdelsameea, Eman, Hassouna, Mona M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976828/
https://www.ncbi.nlm.nih.gov/pubmed/31554369
http://dx.doi.org/10.31557/APJCP.2019.20.9.2723
_version_ 1783490382610300928
author El Mahdy, Hussein Ahmed
Abdelhamid, Ismail Abdelshafy
Amen, Ahmed Ibrahim
Abdelsameea, Eman
Hassouna, Mona M
author_facet El Mahdy, Hussein Ahmed
Abdelhamid, Ismail Abdelshafy
Amen, Ahmed Ibrahim
Abdelsameea, Eman
Hassouna, Mona M
author_sort El Mahdy, Hussein Ahmed
collection PubMed
description BACKGROUND: MicroRNAs are mentioned as a small non-coding RNAs groups and aberrant miRNA expression was found in hepatocellular carcinoma (HCC) patients. AIM: To evaluate role of plasma MicroRNA-215 as a diagnostic tool in HCC patients. METHODS: A prospective study included 195 subjects: healthy controls (group I), cirrhotic patients (group II), and patients with HCC (group III). Clinical examination, radiological and laboratory investigations which included quantification of miR-215 by Real-time qPCR were done for all cases. RESULTS: Spearman’s rank correlation revealed that in HCC group, there was a negative correlation between MiRNA-215 and serum AFP levels and focal size lesion (cm) (rs = -0.72, - 0.94 respectively, p<0.001). Receiver operating characteristics analysis for discrimination between cirrhosis and HCC groups regarding microRNA-215 displayed 78.3% sensitivity, 88.0% specificity at cutoff value of ≤ 1.90. Area under the curve (AUC) was 0.87 (p< 0.001). As regards AFP, it had a sensitivity of 81.7%, a specificity of 66.7 at cutoff value of ≥ 11.50 (ng/mL). CONCLUSIONS: Plasma level of miR-215 may be a promising biomarker in HCC diagnosis. Moreover, if miR-215 combined with AFP, it can be used as a diagnostic biomarker, for early detection of HCC.
format Online
Article
Text
id pubmed-6976828
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-69768282020-02-04 MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma El Mahdy, Hussein Ahmed Abdelhamid, Ismail Abdelshafy Amen, Ahmed Ibrahim Abdelsameea, Eman Hassouna, Mona M Asian Pac J Cancer Prev Research Article BACKGROUND: MicroRNAs are mentioned as a small non-coding RNAs groups and aberrant miRNA expression was found in hepatocellular carcinoma (HCC) patients. AIM: To evaluate role of plasma MicroRNA-215 as a diagnostic tool in HCC patients. METHODS: A prospective study included 195 subjects: healthy controls (group I), cirrhotic patients (group II), and patients with HCC (group III). Clinical examination, radiological and laboratory investigations which included quantification of miR-215 by Real-time qPCR were done for all cases. RESULTS: Spearman’s rank correlation revealed that in HCC group, there was a negative correlation between MiRNA-215 and serum AFP levels and focal size lesion (cm) (rs = -0.72, - 0.94 respectively, p<0.001). Receiver operating characteristics analysis for discrimination between cirrhosis and HCC groups regarding microRNA-215 displayed 78.3% sensitivity, 88.0% specificity at cutoff value of ≤ 1.90. Area under the curve (AUC) was 0.87 (p< 0.001). As regards AFP, it had a sensitivity of 81.7%, a specificity of 66.7 at cutoff value of ≥ 11.50 (ng/mL). CONCLUSIONS: Plasma level of miR-215 may be a promising biomarker in HCC diagnosis. Moreover, if miR-215 combined with AFP, it can be used as a diagnostic biomarker, for early detection of HCC. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC6976828/ /pubmed/31554369 http://dx.doi.org/10.31557/APJCP.2019.20.9.2723 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
El Mahdy, Hussein Ahmed
Abdelhamid, Ismail Abdelshafy
Amen, Ahmed Ibrahim
Abdelsameea, Eman
Hassouna, Mona M
MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma
title MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma
title_full MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma
title_fullStr MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma
title_full_unstemmed MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma
title_short MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma
title_sort microrna-215 as a diagnostic marker in egyptian patients with hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976828/
https://www.ncbi.nlm.nih.gov/pubmed/31554369
http://dx.doi.org/10.31557/APJCP.2019.20.9.2723
work_keys_str_mv AT elmahdyhusseinahmed microrna215asadiagnosticmarkerinegyptianpatientswithhepatocellularcarcinoma
AT abdelhamidismailabdelshafy microrna215asadiagnosticmarkerinegyptianpatientswithhepatocellularcarcinoma
AT amenahmedibrahim microrna215asadiagnosticmarkerinegyptianpatientswithhepatocellularcarcinoma
AT abdelsameeaeman microrna215asadiagnosticmarkerinegyptianpatientswithhepatocellularcarcinoma
AT hassounamonam microrna215asadiagnosticmarkerinegyptianpatientswithhepatocellularcarcinoma